Published in Tob Control on June 01, 2004
The Strategic Dialogue on Tobacco Harm Reduction: a vision and blueprint for action in the US. Tob Control (2009) 3.10
New tobacco products: do smokers like them? Tob Control (2006) 1.21
Developing the science base for reducing tobacco harm. Nicotine Tob Res (2007) 1.15
Chemoprevention of lung carcinogenesis in addicted smokers and ex-smokers. Nat Rev Cancer (2009) 1.09
Consumer awareness and attitudes related to new potential reduced-exposure tobacco product brands. Nicotine Tob Res (2009) 1.07
Impact of corrective health information on consumers' perceptions of "reduced exposure" tobacco products. Tob Control (2007) 0.94
Asian herbal-tobacco cigarettes: "not medicine but less harmful"? Tob Control (2007) 0.93
Characteristics of current and recent former smokers associated with the use of new potential reduced-exposure tobacco products. Nicotine Tob Res (2009) 0.92
Surveillance indicators for potential reduced exposure products (PREPs): developing survey items to measure awareness. Harm Reduct J (2009) 0.76
Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction. Tob Control (2001) 2.64
Reduced smoking: an introduction and review of the evidence. Addiction (2000) 1.79
Tobacco harm reduction: conceptual structure and nomenclature for analysis and research. Nicotine Tob Res (2002) 1.72
Aiding reduction of smoking with nicotine replacement medications: hope for the recalcitrant smoker? Tob Control (1997) 1.68
Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: a randomized trial. J Clin Psychopharmacol (2002) 1.49
Does smoking reduction result in reduction of biomarkers associated with harm? A pilot study using a nicotine inhaler. Nicotine Tob Res (2000) 1.46
Reducing tobacco harm: research challenges and issues. Nicotine Tob Res (2002) 1.44
Two behavioral treatments for smoking reduction: a pilot study. Nicotine Tob Res (2001) 1.15
Long-term follow-up (3-4 years) of treatment for smoking reduction. Addict Behav (1982) 0.86
Signs and symptoms of tobacco withdrawal. Arch Gen Psychiatry (1986) 10.11
Patient exposition and provider explanation in routine interviews and hypertensive patients' blood pressure control. Health Psychol (1987) 2.94
What is a good public participation process? Five perspectives from the public. Environ Manage (2001) 2.37
Smoking cessation in women concerned about weight. Am J Public Health (1992) 1.79
Detection of patients with high alcohol intake by general practitioners. Br Med J (Clin Res Ed) (1986) 1.49
Multiple cholinergic nicotinic receptor genes affect nicotine dependence risk in African and European Americans. Genes Brain Behav (2010) 1.35
Creating tobacco control policy at the local level: implementation of a direct action organizing approach. Health Educ Behav (1997) 1.32
Effects of transdermal nicotine on craving, withdrawal and premenstrual symptomatology in short-term smoking abstinence during different phases of the menstrual cycle. Nicotine Tob Res (2000) 1.32
Symptomatology and energy intake during the menstrual cycle in smoking women. J Subst Abuse (1996) 1.23
Characteristics of 275 patients with bulimia. Am J Psychiatry (1985) 1.19
Physician communication to patients regarding medications. Patient Educ Couns (1985) 1.17
Steep central islands after myopic photorefractive keratectomy. J Cataract Refract Surg (1998) 1.14
Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. J Clin Virol (2001) 1.11
Smoking topography in tobacco chippers and dependent smokers. Addict Behav (1996) 1.06
Methodological considerations in children's focus groups. Nurs Res (2001) 1.02
Characterization of tobacco withdrawal: physiological and subjective effects. NIDA Res Monogr (1985) 1.00
Electrolyte and other physiological abnormalities in patients with bulimia. Psychol Med (1983) 0.97
Deglycosylation of chondroitin sulfate proteoglycan by hydrogen fluoride in pyridine. Anal Biochem (1985) 0.93
What are atypical eating disorders? Psychosomatics (1986) 0.93
The effect of combination antiretroviral therapy on CD5 B- cells, B-cell activation and hypergammaglobulinaemia in HIV-1-infected patients. HIV Med (2005) 0.91
A comparison study of antidepressants and structured intensive group psychotherapy in the treatment of bulimia nervosa. Arch Gen Psychiatry (1990) 0.88
Delay in consulting a medical practitioner about rectal bleeding. J Epidemiol Community Health (1992) 0.88
National working conference on smoking and body weight. Task Force 1: Mechanisms relevant to the relations between cigarette smoking and body weight. Health Psychol (1992) 0.88
Interns' performances with simulated patients at the beginning and the end of the intern year. J Gen Intern Med (1992) 0.87
High-dose naltrexone therapy and dietary counseling for obesity. Biol Psychiatry (1987) 0.87
Percentage of CD3+CD4-CD8-gammadeltaTCR- T cells is increased HIV disease. AIDS Res Hum Retroviruses (2001) 0.87
Posttreatment depression in an alcohol and drug abuse population. Am J Psychiatry (1982) 0.86
Adolescent use of sun-protection measures. Med J Aust (1989) 0.84
Characteristics of patients with bulimia only, bulimia with affective disorder, and bulimia with substance abuse problems. Addict Behav (1986) 0.84
Reliability of naevus counts in identifying individuals at high risk of malignant melanoma. Br J Dermatol (1994) 0.84
Bulimia nervosa in overweight individuals. J Nerv Ment Dis (1990) 0.82
Effects of high intravenous doses of dynorphin A(1-13) on tail flick latency and central nervous system histology in rats. Pharmacol Biochem Behav (1995) 0.82
Relapse among alcoholics with phobic and panic symptoms. Addict Behav (1992) 0.82
Bulimia nervosa with and without a history of anorexia nervosa. Compr Psychiatry (1990) 0.81
Graves' disease during immune reconstitution after highly active antiretroviral therapy for HIV infection: evidence of thymic dysfunction. AIDS Res Hum Retroviruses (2004) 0.81
Serial monitoring of T-cell subset ratios with monoclonal antibodies in steroid- and antithymocyte globulin-treated patients with renal allotransplants. Clin Immunol Immunopathol (1984) 0.80
Synthesis and structure of proteoglycan core protein. Fed Proc (1985) 0.80
Energy intake and energy expenditure during the menstrual cycle in short-term smoking cessation. Addict Behav (2001) 0.80
The hemolytic uremic syndrome, with positive immunofluorescence studies. J Pediatr (1974) 0.79
Cholesterol changes in smoking cessation using the transdermal nicotine system. Transdermal Nicotine Study Group. Prev Med (1994) 0.79
The prevalence and sociodemographic correlates of high-risk and problem drinking at an industrial worksite. Br J Addict (1990) 0.79
Mutation analysis of the seven in absentia homolog 1 (SIAH1) gene in Parkinson's disease. J Neural Transm (Vienna) (2006) 0.78
Chondroitin sulfate proteoglycan expression during neuronal development. Cell Mol Biol (Noisy-le-grand) (1993) 0.78
Maintenance treatment and 6-month outcome for bulimic patients who respond to initial treatment. Am J Psychiatry (1990) 0.78
Requesting previous psychiatric records. Do they come and are they worth obtaining? J Nerv Ment Dis (1981) 0.78
Smokeless tobacco cessation. Prim Care (1999) 0.78
Bulimia nervosa with and without a history of overweight. J Subst Abuse (1990) 0.78
Advances in controlling hypertension in low-income patients. Am J Prev Med (1988) 0.78
Effects of dynorphin A(1-13) on opiate withdrawal in humans. Psychopharmacology (Berl) (1998) 0.78
A comparative analysis of psychiatric problems listed by patients and physicians. Hosp Community Psychiatry (1983) 0.77
Bulimia with and without a family history of depressive illness. Compr Psychiatry (1986) 0.77
Affective disorder and substance abuse in women with bulimia. Psychol Med (1984) 0.77
DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A(*)2402 resulting in loss of HLA allele expression. Leukemia (2004) 0.77
Chewing and spitting out food as a clinical feature of bulimia. Psychosomatics (1988) 0.77
Similarities and differences on the MMPI between women with bulimia and women with alcohol or drug abuse problems. Addict Behav (1982) 0.76
Agreement between two measures of drug use in a low-prevalence population. Addict Behav (1991) 0.76
Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention. Pharmacopsychiatry (1985) 0.76
The bulimia syndrome: course of the illness and associated problems. Compr Psychiatry (1986) 0.76
Feasibility of sigmoidoscopic screening for colorectal cancer in the Hunter Region. Aust N Z J Surg (1990) 0.76
Correlation between eyes in bilateral LASIK. Ophthalmology (2000) 0.75
Topical diclofenac sodium after excimer laser phototherapeutic keratectomy. J Refract Surg (1997) 0.75
Asphyxia and resuscitation. Minn Med (1979) 0.75
Self-concept changes during youth-home placement of adolescents. Adolescence (1987) 0.75
Late onset bulimia. Compr Psychiatry (1987) 0.75
Professional needs of palliative care nurses in New South Wales. Palliat Med (1995) 0.75
Response to alternative antidepressants in imipramine nonresponders with bulimia nervosa. J Clin Psychopharmacol (1989) 0.75
The reliability and stability of the Mortimer-Filkins test. J Stud Alcohol (1992) 0.75
The dexamethasone suppression test in patients with bulimia. J Clin Psychiatry (1984) 0.75
The Mississippi Transplant Program: scope and results. J Miss State Med Assoc (1983) 0.75
The influence of prior alcohol and drug abuse problems on bulimia nervosa treatment outcome. Addict Behav (1990) 0.75
Laxative abuse as a variant of bulimia. J Nerv Ment Dis (1986) 0.75
Minors' access to snuff: purchase outcomes at corporate owned and independently owned convenience stores. Addict Behav (2000) 0.75
The changing population of bulimia nervosa patients in an eating disorders program. Hosp Community Psychiatry (1989) 0.75
Body composition and plasma lipid and stress hormone levels during 3 weeks of feed restriction and refeeding in low birth weight female pigs. J Anim Sci (2015) 0.75
Effects of treatment on cardiovascular risk among smokeless tobacco users. Prev Med (1995) 0.75
Enema abuse as a clinical feature of bulimia nervosa. Psychosomatics (1991) 0.75
[The ultraviolet laser in the treatment of keratomycoses]. Bull Mem Soc Fr Ophtalmol (1986) 0.75
Short-term effects of nicotine gum. NIDA Res Monogr (1985) 0.75
Relationship between chronic ovine dermatophilosis and levels of T6 lymphocyte antigen staining in peripheral blood mononuclear cells. Vet Microbiol (1992) 0.75
Post-treatment depressive symptoms and relapse to drug use in different age groups of an alcohol and other drug abuse population. Drug Alcohol Depend (1981) 0.75
Bulimia with and without a family history of drug abuse. Addict Behav (1988) 0.75
Physical symptoms reported by patients with bulimia and patients with depression. Psychiatr Med (1988) 0.75
15 years of experience with renal replacement therapy in patients starting therapy before age 20. Int J Artif Organs (1988) 0.75
Antidepressants vs. group therapy in the treatment of bulimia. Psychopharmacol Bull (1987) 0.75
Anti-class II antibody production prolongs renal allograft survival. Pathol Immunopathol Res (1989) 0.75